{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:27:35Z","timestamp":1762630055480,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:44:46Z","timestamp":1724831086000},"page":"1111-1117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status"],"prefix":"10.1016","volume":"8","author":[{"given":"Yann","family":"Neuzillet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Raynaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cam\u00e9lia","family":"Radulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Rouanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Krish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Comperat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Galiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Cathelineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Validire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Molini\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Fiet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Giton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Botto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.08.003_b0005","doi-asserted-by":"crossref","first-page":"6s33","DOI":"10.1016\/S1166-7087(22)00173-7","volume":"32","author":"Lasserre","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","article-title":"Active surveillance for prostate cancer: a systematic review of the literature","volume":"62","author":"Dall'Era","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: what does it mean?","volume":"44","author":"Tourinho-Barbosa","year":"2018","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000468947","article-title":"Gleason score within prostate abnormal areas defined by multiparametric magnetic resonance imaging did not vary according to the PIRADS score","volume":"99","author":"Slaoui","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2024.08.003_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.juro.2014.07.123","article-title":"The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy","volume":"193","author":"Klap","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0030","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.mayocp.2016.04.007","article-title":"Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions","volume":"91","author":"Morgentaler","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.euo.2024.08.003_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12672-018-0351-8","article-title":"Aggressiveness of localized prostate cancer: the key value of testosterone deficiency evaluated by both total and bioavailable testosterone: AndroCan study results","volume":"10","author":"Neuzillet","year":"2019","journal-title":"Horm Cancer"},{"key":"10.1016\/j.euo.2024.08.003_b0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Endogenous Hormones and Prostate Cancer Collaborative Group","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2024.08.003_b0045","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1996.03540230054035","article-title":"Occult prostate cancer in men with low serum testosterone levels","volume":"276","author":"Morgentaler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.08.003_b0050","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.urology.2006.08.1058","article-title":"Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0\u00a0ng\/mL or less","volume":"68","author":"Morgentaler","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.003_b0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pros.1046","article-title":"High-grade prostate cancer is associated with low serum testosterone levels","volume":"47","author":"Schatzl","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2024.08.003_b0060","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2024.08.003_b0065","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1210\/jc.2008-1902","article-title":"The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men","volume":"94","author":"Brambilla","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2024.08.003_b0070","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1210\/jc.2013-3375","article-title":"Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism","volume":"98","author":"Handelsman","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2024.08.003_b0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1530\/EJE-08-0601","article-title":"Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations","volume":"159","author":"Wang","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.euo.2024.08.003_b0080","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1210\/jc.2014-2658","article-title":"Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotropic hypogonadism and panhypopituitarism: a GCMS-based comparative study","volume":"100","author":"Giton","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2024.08.003_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-7525-1-15","article-title":"The Aging Males' Symptoms (AMS) scale: update and compilation of international versions","volume":"1","author":"Heinemann","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euo.2024.08.003_b0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.euo.2024.08.003_b0095","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part II: recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0105","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2024.08.003_b0110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/pcan.2015.44","article-title":"Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading","volume":"18","author":"Pichon","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.08.003_b0120","doi-asserted-by":"crossref","first-page":"12730","DOI":"10.3390\/ijms232112730","article-title":"On the need to distinguish between insulin-normal and insulin-resistant patients in testosterone therapy","volume":"23","author":"Zolla","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2024.08.003_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4732021","article-title":"Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: a meta-analysis","volume":"2020","author":"Li","year":"2020","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.euo.2024.08.003_b0130","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.biopha.2017.05.119","article-title":"Antidepressive effects of ginsenoside Rg1 via regulation of HPA and HPG axis","volume":"92","author":"Mou","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euo.2024.08.003_b0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/js.2018-00186","article-title":"The anti-inflammatory effects of testosterone","volume":"3","author":"Bianchi","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.euo.2024.08.003_b0140","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.urology.2008.06.001","article-title":"Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy","volume":"72","author":"Lane","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.003_b0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21681805.2022.2108140","article-title":"Biochemical recurrence after radical prostatectomy - a large, comprehensive, population-based study with long follow-up","volume":"56","author":"Ax\u00e9n","year":"2022","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clgc.2018.01.005","article-title":"Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis","volume":"16","author":"Claps","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2024.08.003_b0155","doi-asserted-by":"crossref","first-page":"E541","DOI":"10.1111\/j.1464-410X.2012.11232.x","article-title":"Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment","volume":"110","author":"Garcia-Cruz","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.003_b0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00345-011-0793-x","article-title":"Low serum testosterone levels are predictive of prostate cancer","volume":"31","author":"Mearini","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.08.003_b0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bju.13206","article-title":"Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy","volume":"118","author":"Park","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.003_b0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41585-022-00686-y","article-title":"The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications","volume":"20","author":"Kumar","year":"2023","journal-title":"Nat Rev Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:25Z","timestamp":1762629985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931124001913"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}